Search

Your search keyword '"Hannan, N"' showing total 93 results
Start Over Author "Hannan, N" Publication Year Range Last 10 years
93 results on '"Hannan, N"'

6. Enoxaparin for the prevention of preeclampsia and intrauterine growth restriction in women with a history: a randomized trial

Author

Groom, Katie M., McCowan, Lesley M., Mackay, Laura K., Lee, Arier C., Said, Joanne M., Kane, Stefan C., Walker, Susan P., van Mens, Thijs E., Hannan, Natalie J., Tong, Stephen, Chamley, Larry W., Stone, Peter R., McLintock, Claire, Groom, K., McCowan, L., Mackay, L., Lee, A., Stone, P., Chamley, L., McLintock, C., Said, J., Kane, S., Walker, S., Tong, S., Hannan, N., van Mens, T., Ganzevoort, W., and Middeldorp, S.

Published
2017
Full Text
View/download PDF

7. S117 Poor adherence in exacerbating COPD patients: magnitude and related factors at baseline in the MAGNIFY pragmatic trial

Author

Dickens, AP, primary, Halpin, DMG, additional, Carter, V, additional, Skinner, D, additional, Beeh, K, additional, Chalmers, J, additional, Clark, A, additional, Hannan, N, additional, Kaplan, A, additional, Kostikas, K, additional, Pinnock, H, additional, Roche, N, additional, Usmani, O, additional, van Boven, JFM, additional, Mastoridis, P, additional, Mezzi, K, additional, Davis, S, additional, Vijaykumar, E, additional, and Price, D, additional

Published
2022
Full Text
View/download PDF

8. P186 Facilitators to recruiting COPD patients to an adherence intervention trial

Author

Dickens, AP, primary, Halpin, DMG, additional, Carter, V, additional, Skinner, D, additional, Beeh, K, additional, Chalmers, J, additional, Clark, A, additional, Hannan, N, additional, Kaplan, A, additional, Kostikas, K, additional, Pinnock, H, additional, Roche, N, additional, Usmani, O, additional, van Boven, JFM, additional, Mastoridis, P, additional, Mezzi, K, additional, Davis, S, additional, Vijaykumar, E, additional, and Price, D, additional

Published
2022
Full Text
View/download PDF

10. Patient-reported barriers to accepting a technological adherence package in the MAGNIFY trial.

Author

Dickens, A, primary, Halpin, D, additional, Carter, V, additional, Skinner, D, additional, Beeh, K, additional, Chalmers, J, additional, Clark, A, additional, Hannan, N, additional, Kaplan, A, additional, Kostikas, K, additional, Pinnock, H, additional, Roche, N, additional, Usmani, O, additional, Boven, J F V, additional, Mastoridis, P, additional, Mezzi, K, additional, Davis, S, additional, and Price, D, additional

Published
2022
Full Text
View/download PDF

11. Pravastatin, proton-pump inhibitors, metformin, micronutrients, and biologics: new horizons for the prevention or treatment of preeclampsia

Author

Tong, S, Kaitu'u-Lino, TJ, Hastie, R, Brownfoot, F, Cluver, C, Hannan, N, Tong, S, Kaitu'u-Lino, TJ, Hastie, R, Brownfoot, F, Cluver, C, and Hannan, N

Abstract

There has been increasing research momentum to identify new therapeutic agents for the prevention or treatment of preeclampsia, drugs that can affect the underlying disease pathophysiology. Molecular targets of candidate treatments include oxidative stress, antiangiogenic factors, and the angiotensin, nitric oxide, and proinflammatory pathways. The proposed treatments undergoing preclinical and clinical trial evaluation are thought to act on placental or endothelial disease or both. Most have adopted the pragmatic strategy of repurposing drugs. Of all the therapeutic agents proposed, pravastatin has received the most interest. There are preclinical studies showing that it has pleiotropic actions that favorably impact on multiple molecular targets and can resolve a preeclampsia phenotype in many animal models. An early phase clinical trial suggests that it may have therapeutic activity. Several large prevention trials are planned or ongoing and, when completed, could definitively address whether pravastatin can prevent preeclampsia. Proton-pump inhibitors, metformin, and sulfasalazine are other drugs with preclinical evidence of multiple molecular actions that could resolve the pathophysiology of preeclampsia. These agents are also currently being evaluated in clinical trials. There have been many recent preclinical studies identifying the potential of numerous natural compounds to treat preeclampsia, such as plant extracts and micronutrients that have potent anti-inflammatory or antioxidant activity. Recent preclinical studies have also proposed novel molecular-targeted strategies, such as monoclonal antibodies targeting tumor necrosis factor alpha, placental growth factor, and short interfering RNA technology, to silence the gene expression of soluble fms-like tyrosine kinase-1 or angiotensinogen. Other treatment approaches that have transitioned to human trials (ranging from single-arm to phase III trials that have been completed or are ongoing) include folic acid

Published
2022

12. Hydroxychloroquine reduces soluble Flt-1 secretion from human cytotrophoblast, but does not mitigate markers of endothelial dysfunction in vitro

Author

Bolego, C, Kadife, E, Hannan, N, Harper, A, Binder, N, Beard, S, Brownfoot, FC, Bolego, C, Kadife, E, Hannan, N, Harper, A, Binder, N, Beard, S, and Brownfoot, FC

Abstract

Preeclampsia is a multi-system disease that can have severe, even fatal implications for the mother and fetus. Abnormal placentation can lead to ischaemic tissue injury and placental inflammation. In turn, the placenta releases anti-angiogenic factors into the maternal circulation. These systemically act to neutralise angiogenic factors causing endothelial dysfunction causing preeclampsia. Hydroxychloroquine is an immune modulating drug that is considered safe in pregnancy. There is epidemiological evidence suggesting it may reduce the risk of preeclampsia. Here, we examined the effects hydroxychloroquine on the production and secretion of sFlt-1, soluble endoglin (sENG), placental growth factor (PlGF) and vascular endothelial growth factor (VEGF) in primary human placenta, cytotrophoblasts and umbilical vein endothelial cells (endothelial cell model). Hydroxychloroquine treatment decreased mRNA expression of two sFlt-1 isoforms and its protein secretion. sENG was not reduced. Hydroxychloroquine treatment increased secretion of pro-angiogenic factor PIGF from endothelial cells. It did not significantly reduce the expression of the endothelial cell inflammation marker, ET-1, and inflammation induced expression of the adhesion molecule, VCAM. Hydroxychloroquine could not overcome leukocyte adhesion to endothelial cells. Hydroxychloroquine mitigates features of preeclampsia, but it does not reduce key markers of endothelial dysfunction.

Published
2022

17. The effects of N-acetyl cysteine on acute viral respiratory infections in humans: A rapid review

Author

Schloss J, Leach M, Brown D, Hannan N, Kendall-Reed P, and Steel A

Subjects
1104 Complementary and Alternative Medicine, 1111 Nutrition and Dietetics, 1117 Public Health and Health Services
Abstract

Current evidence suggests that N-Acetyl Cysteine (NAC) administration may help improve outcomes in people with acute respiratory distress syndrome and acute lung injury - conditions that closely resemble the signs and symptoms of COVID-19. Few mild and transient adverse events were reported in published randomised-controlled trials, indicating that NAC may be reasonably safe. These findings suggest that NAC may complement the management of COVID-19 infection, particularly when administered intravenously within an intensive care unit (ICU) environment. Verdict Current evidence suggests that N-Acetyl Cysteine (NAC) administration may help improve outcomes in people with acute respiratory distress syndrome (ARDS) and acute lung injury (ALI) - conditions that closely resemble the signs and symptoms of COVID-19. In this rapid review, NAC was predominately administered intravenously to patients with ARDS or ALI, who were at risk of or requiring mechanical ventilation, and were admitted to a hospital intensive care unit. Findings indicated that NAC administration may assist in improving markers of inflammation or oxidation, systemic oxygenation, the need for / duration of ventilation, rate of patient recovery and clinical improvement score. The effects of NAC on patient length of stay, CT/x-ray images, mortality rate and pulmonary complications were inconclusive. Few mild and transient adverse events were noted, indicating that NAC may be safe for use in acute respiratory distress syndrome or acute lung injury. Based on the evidence identified, and the similar symptomatic profiles of ARDS/ALI and COVID-19, the findings suggest that NAC may be used to complement the management of COVID-19 infection within an acute care setting. The safety and efficacy of orally administered NAC for the management of milder forms of COVID-19 infection within the community setting, remains uncertain. The current research evidence suggests NAC warrants further research for acute respiratory viral infections, including COVID-19.

Published
2020

18. The effect of Echinacea spp. on the prevention or treatment of COVID-19 and other respiratory tract infections in humans: A rapid review

Author

Aucoin, M, Cooley, K, Saunders, PR, Carè, J, Anheyer, D, Medina, DN, Cardozo, V, Remy, D, Hannan, N, and Garber, A

Subjects
1104 Complementary and Alternative Medicine, 1111 Nutrition and Dietetics, 1117 Public Health and Health Services
Abstract

Brief overviewCurrent evidence suggests that Echinacea supplementation may decrease the duration and severity of acute respiratory tract infections; however, no studies using Echinacea in the prevention or treatment of conditions similar to COVID-19 have been identified. Few adverse events were reported, suggesting that this herbal therapy is reasonably safe. Because Echinacea can increase immune function, there is a concern that it could worsen over-activation of the immune system in cytokine storm; however, clinical trials show that Echinacea decreases levels of immune molecules involved in cytokine storm.VerdictEchinacea supplementation may assist with the symptoms of acute respiratory infections (ARI) and the common cold, particularly when administered at the first sign of infection; however, no studies using Echinacea in the prevention or treatment of conditions similar to COVID-19 have been identified. Previous studies have reported that Echinacea may decrease the severity and/or duration of ARI when taken at the onset of symptoms. The studies reporting benefit used E. purpurea or a combination of E. purpurea and E. angustifolia containing standardized amounts of active constituents.Few adverse events from the use of Echinacea were reported, suggesting that this herbal therapy is reasonably safe. No human trials could be located reporting evidence of cytokine storm when Echinacea was used for up to 4 months.When assessing all human trials which reported changes in cytokine levels in response to Echinacea supplementation, the results were largely consistent with a decrease in the pro-inflammatory cytokines that play a role in the progression of cytokine storm and Acute Respiratory Distress Syndrome (ARDS), factors that play a significant role in the death of COVID-19 patients. While there is currently no research on the therapeutic effects of Echinacea in the management of cytokine storm, this evidence suggests that further research is warranted.

Published
2020

19. Multivitamins for acute respiratory tract infections: a rapid review

Author

Cramer H, Hannan N, Schloss J, Leach M, Lloyd I, and Steel A

Subjects
food and beverages, 1104 Complementary and Alternative Medicine, 1111 Nutrition and Dietetics, 1117 Public Health and Health Services
Abstract

Brief Overview Seven human clinical trials with some risk of bias suggest that multivitamins may be a safe and effective intervention to relieve some symptoms of respiratory tract infections, increase micronutrient status and immune function; however, further research is needed. There is currently insufficient evidence to recommend multivitamins as a therapy for the treatment or prevention of COVID-19. Verdict The overall quality of research examining the effect of prophylactic multivitamin supplementation on the effects of the acute respiratory tract infections (ARTI) is weak. Most of the available research included adults aged 50 years or over recruited through either the community or institutional settings (i.e. hospital facility, residential care facility). The multivitamin supplements used contained at least five vitamins and minerals and were administered between three months and two years (median: 15 months). Based on the available evidence, multivitamin supplementation does not appear to reduce the incidence of ARTI or mortality (both ARTI-related and all-cause). The effect of multivitamins taken before infection on the duration of ARTI is unclear due to conflicting results across studies. Multivitamins may, however, reduce the symptoms associated with ARTI such as headache, conjunctivitis, and activity restriction but not the overall symptom scores. No differences in health service visits, inclusive of primary and tertiary care, has been identified for individuals taking a multivitamin prior to an ARTI.

Published
2020

22. PSG9-A NOVEL BIOMARKER DERANGED IN PREECLAMPSIA

Author

Kandel, M, Walker, S, MacDonald, T, Cluver, C, Bergman, L, Myers, J, Hastie, R, Keenan, E, Cannon, P, Nguyen, T-V, Hannan, N, Pritchard, N, Tong, S, Kaitu'u-Lino, T, Kandel, M, Walker, S, MacDonald, T, Cluver, C, Bergman, L, Myers, J, Hastie, R, Keenan, E, Cannon, P, Nguyen, T-V, Hannan, N, Pritchard, N, Tong, S, and Kaitu'u-Lino, T

Published
2021

24. What influences complementary medicine use for children with eosinophilic esophagitis? Findings from a cross-sectional survey.

Author

Hannan, N, Steel, A, Tiralongo, E, McMillan, SS, Hannan, N, Steel, A, Tiralongo, E, and McMillan, SS

Abstract

Background and purpose Utilization of complementary medicines (CMs) amongst children with eosinophilic esophagitis (EoE) in Australia is high. Carers' beliefs, perceptions and use of CM can influence the decision to use CM in children in their care. This study explores the factors influencing the use of CM for a child's EoE when the carer also uses CM. Materials and methods Carers of children aged 0–18 years with EoE participated in a national cross-sectional online survey, conducted in Australia between September 2018 and February 2019. Data analysis included bivariate analysis, Cramer's V, backwards stepwise logistic regression and binomial logistic regression. Results Of the 181 total survey responses, 165 (91.2 %) respondents indicated they had utilized some form of CM for themselves. Children whose carer had used some form of CM for themselves were more likely to have used CM than children whose carer had not used CM (OR 4.6; p = 0.001). Of the CM self-using carers, 125 (75.8 %) had also chosen to utilize CM for their child's EoE. Use of CM in children was more likely amongst children who had used a pharmaceutical for their EoE (OR 7.51; p = 0.010), and those whose carer had consulted with “other health practitioners or health workers” for their child's EoE (OR 5.34; p < 0.001) or had consulted with a chiropractor for themselves (OR 2.70; p = 0.029). Conclusion High CM self-use amongst carers is associated with their decision to also use CM for their child's EoE, a concern given the absence of evidence for CM's safety and efficacy in this population. CM use in this population warrants further attention. Effective conventional medicines for EoE are limited and utilization of CM amongst children with EoE in Australia is high. The recommendation of CM for children with EoE warrants further attention given the substantial concomitant pharmaceutical care, and the absence of evidence for CM's safety and efficacy in this population. Further research into the role of C

Published
2021

25. Treatment Burden for Pediatric Eosinophilic Esophagitis: A Cross-Sectional Survey of Carers.

Author

Hannan, N, McMillan, SS, Tiralongo, E, Steel, A, Hannan, N, McMillan, SS, Tiralongo, E, and Steel, A

Abstract

OBJECTIVE: To investigate treatment burden and impact on health-related quality of life (HRQoL) for children with eosinophilic esophagitis (EoE) and their carers. METHODS: An Australian cross-sectional online survey of carers of children aged 18 years and under with EoE between September 2018 to February 2019. RESULTS: Of 181 complete responses, more than half of carers experienced reduced HRQoL since their child's diagnosis. Reported mean out-of-pocket expenditure for healthcare utilization (practitioner visits and treatment) was AUD$3064.3 annually. Backwards stepwise linear regression models showed that reduced ability to manage on income and missing more than one workday in the previous 30 days were significant predictors of lower carer HRQoL. Ability to manage on the current income described as "difficult some of the time," "difficult all of the time," and "impossible" were associated with lower child HRQoL. When compared with EoE diagnosis between 13 and 23 months of age, diagnosis between 2 and 4 years was a significant predictor of lowered child HRQoL. CONCLUSIONS: Pediatric EoE in Australia leads to high treatment burden for carers. Changes in carer employment and income manageability can negatively impact carer psychosocial wellbeing. Carers of children with EoE need to be informed about available financial and social support to reduce treatment-related burden and improve the quality of life of both the carer and child.

Published
2021

27. Health Service Use and Treatment Choices for Pediatric Eosinophilic Esophagitis: Findings From a Cross-Sectional Survey of Australian Carers

Author

Hannan, N, Steel, A, McMillan, SS, Tiralongo, E, Hannan, N, Steel, A, McMillan, SS, and Tiralongo, E

Abstract

© Copyright © 2020 Hannan, Steel, McMillan and Tiralongo. Objectives: The incidence and the prevalence of eosinophilic esophagitis (EoE) are increasing, and healthcare utilization among children with EoE is high. This study provides novel insights into the health services and the treatments, including complementary medicines (CMs), used by carers to manage their children's EoE as well as the carers' beliefs and attitudes toward these treatments. Methods: A national cross-sectional online survey was conducted in Australia between September 2018 and February 2019. The survey included questions about health service and treatment utilization, health insurance and government support, health-related quality of life of children with EoE and their carers, views and attitudes toward CM use, and perceived efficacy of treatment. Results: The survey was completed by 181 carers (96.6% of whom were mothers) of EoE children. Most children (91.2%, n = 165) had seen a medical doctor for their EoE, and almost half had consulted with a CM practitioner (40.3%, n = 73). Pharmaceuticals (n = 156, 86.2%) were the most commonly used treatment option, followed by dietary changes (n = 142, 78.5%), CM products (n = 109, 60.2%), and CM therapies (n = 42, 23.2%). Most children received care from numerous practitioners on multiple occasions, indicating a substantial financial and treatment-related burden. Conclusions: A variety of practitioners are involved in the care of children with EoE, and a high rate of CM use warrants further attention to ensure that appropriate treatment is provided. Carer involvement and guidance, combined with individual practitioner expertise, referrals, and collaboration between providers, is essential to successfully navigate this complex disease and provide adequate care for these patients.

Published
2020

28. Efficacy and safety of vitamin C in the management of acute respiratory infection and disease: A rapid review.

Author

Schloss, J, Lauche, R, Harnett, J, Hannan, N, Brown, D, Greenfield, T, Steel, A, Schloss, J, Lauche, R, Harnett, J, Hannan, N, Brown, D, Greenfield, T, and Steel, A

Abstract

Brief overview Current evidence from published systematic reviews indicate that oral intake of vitamin C may assist with symptoms of acute viral respiratory infections (ARI) by reducing fever and chills, relieving chest pain and assist in reducing symptoms of common cold-induced asthma. Intravenous (IV) vitamin C administration may reduce the need for vasopressor support and the duration of mechanical ventilations in critically ill patients in hospital. COVID-19 has similar signs and symptoms of ARI. Further studies involving patients with COVID-19, either through administration of oral vitamin C in mild cases or IV vitamin C in critical cases, would be advantageous to examine if it is safe and efficacious. Verdict Oral vitamin C may assist with the symptoms of acute respiratory viral infections (ARI) and common cold-induced asthma but no studies have been identified justifying oral vitamin C for the prevention or treatment of coronavirus infections including COVID-19. When taken at onset of ARI, oral vitamin C may reduce the duration of symptoms including fever, chest pain, chills and bodily aches and pains. It may also reduce the incidence of hospital admission and duration of hospital stays. For individuals admitted to hospital with community-acquired pneumonia, vitamin C may improve respiratory function in more severe cases. No major adverse events nor interactions were reported by either method of administration. However, there is an absence of high quality, contemporary clinical research examining this topic. Current evidence suggests further studies are needed to better understand the value of both oral and IV vitamin C for ARI, including COVID-19.

Published
2020

29. The effect of quercetin on the prevention or treatment of COVID-19 and other respiratory tract infections in humans: A rapid review.

Author

Aucoin, M, Cooley, K, Saunders, PR, Cardozo, V, Remy, D, Cramer, H, Neyre Abad, C, Hannan, N, Aucoin, M, Cooley, K, Saunders, PR, Cardozo, V, Remy, D, Cramer, H, Neyre Abad, C, and Hannan, N

Abstract

Brief overview

There is currently insufficient evidence to recommend quercetin supplementation as a therapy for the treatment or prevention of COVID-19. Three human clinical trials with low risk of bias suggest that oral quercetin may have a beneficial effect on the incidence and duration of respiratory tract infections in certain populations; however, further research is needed.

Verdict

Current evidence on the efficacy of quercetin supplementation in the treatment and prevention of COVID-19 is insufficient for its clinical recommendation at this time. Quercetin exhibits both immunomodulatory and antimicrobial effects in preclinical studies; however, only three human clinical trials, each with a low risk of bias rating, were identified in this rapid review. One study reported a decrease in incidence of upper respiratory tract infections following a competitive athletic event. A larger community clinical trial reported a benefit in older, athletic adults only.

Published
2020

33. World Congress Integrative Medicine & Health 2017: part two Berlin, Germany. 3-5 May 2017 Abstracts

Author

Ee, C, Thuraisingam, S, Pirotta, M, French, S, Xue, C, Teede, H, Kristoffersen, AE, Sirois, F, Stub, T, Engler, J, Joos, S, Güthlin, C, Felenda, J, Beckmann, C, Stintzing, F, Evans, R, Bronfort, G, Keefe, D, Taberko, A, Hanson, L, Haley, A, Ma, H, Jolton, J, Yarosh, L, Keefe, F, Nam, J, Ojala, L, Kreitzer, MJ, Fink, C, Kraft, K, Flower, A, Lewith, G, Harman, K, Stuart, B, Bishop, FL, Frawley, J, Füleki, L, Kiss, E, Vancsik, T, Krenacs, T, Funabashi, M, Pohlman, KA, Mior, S, Thiel, H, Hill, MD, Cassidy, DJ, Westaway, M, Yager, J, Hurwitz, E, Kawchuk, GN, O’Beirne, M, Vohra, S, Gaboury, I, Morin, C, Gaertner, K, Torchetti, L, Frei-Erb, M, Kundi, M, Frass, M, Gallo, E, Maggini, V, Comite, M, Sofi, F, Baccetti, S, Vannacci, A, Di Stefano, M, Monechi, MV, Gori, L, Rossi, E, Firenzuoli, F, Mediati, RD, Ballerini, G, Gardiner, P, Lestoquoy, AS, Negash, L, Stillman, S, Shah, P, Liebschutz, J, Adelstein, P, Farrell-Riley, C, Brackup, I, Penti, B, Saper, R, Sampedro, IG, Carvajal, G, Gleiss, A, Gross, MM, Brendlin, D, Röttger, J, Stritter, W, Seifert, G, Grzanna, N, Stange, R, Guendling, PW, Gu, W, Lu, Y, Wang, J, Zhang, C, Bai, H, He, Y, Zhang, X, Zhang, Z, Wang, D, Meng, F, Hagel, A, Albrecht, H, Vollbracht, C, Dauth, W, Hagel, W, Vitali, F, Ganzleben, I, Schultis, H, Konturek, P, Stein, J, Neurath, M, Raithel, M, Krick, B, Haller, H, Klose, P, Dobos, G, Kümmel, S, Cramer, H, Saha, FJ, Kowoll, A, Ebner, B, Berger, B, Choi, K-E, He, L, Wang, H, He, X, Gu, C, Zhang, Y, Zhao, L, Tong, X, Ho, RST, Chung, VCH, Wu, X, Wong, CHL, Wu, JCY, Wong, SYS, Lau, AYL, Sit, RWS, Wong, W, Holmes, M, Bishop, F, Calman, L, Newell, D, Field, J, Htut, WL, Han, D, Choi, DI, Choi, SJ, Kim, HY, Hwang, JH, Huang, CW, Jang, BH, Chen, FP, Ko, SG, Huang, W, Jin, D, Lian, F, Jang, S, Kim, KH, Lee, EK, Sun, SH, Go, HY, Ko, Y, Park, S, Shin, YC, Janik, H, Greiffenhagen, N, Bolte, J, Jaworski, M, Adamus, M, Dobrzynska, A, Jeitler, M, Jaspers, J, von Scheidt, C, Koch, B, Michalsen, A, Steckhan, N, Kessler, C, Huang, W-J, Pang, B, Lian, F-M, Jong, M, Baars, E, Glockmann, A, Hamre, H, Kainuma, M, Murakami, A, Kubota, T, Kobayashi, D, Sumoto, Y, Furusyo, N, Ando, S-I, Shimazoe, T, Kelber, O, Verjee, S, Gorgus, E, Schrenk, D, Kemper, K, Hill, E, Rao, N, Gascon, G, Mahan, J, Kienle, G, Dietrich, J, Schmoor, C, Huber, R, Kim, WH, Ahmed, M, Meggyeshazi, N, Kovago, C, Klaus, AK, Zerm, R, Pranga, D, Ostermann, T, Reif, M, von Laue, HB, Brinkhaus, B, Kröz, M, Recchia, DR, Klein-Laansma, CT, von Hagens, C, Jansen, JP, van Wietmarschen, H, Jong, MC, Sun, S-H, Go, H-Y, Jeon, C-Y, Song, Y-K, Ko, S-G, Koch, AK, Rabsilber, S, Lauche, R, Langhorst, J, Trifunovic-Koenig, M, Koster, E, Delnoij, D, Kroll, L, Weiss, K, Kubo, A, Hendlish, S, Altschuler, A, Connolly, N, Avins, A, Wardle, J, Lee, D, Sibbritt, D, Adams, J, Park, C, Mishra, G, Lechner, J, Lee, I, Chae, Y, Lee, J, Cho, SH, Choi, Y, Lee, JY, Ryu, HS, Yoon, SS, Oh, HK, Hyun, LK, Kim, JO, Yoon, SW, Lee, J-Y, Shin, S-H, Jang, M, Müller, I, Park, S-HJ, Laird, L, Mitchell, S, Li, X, Wang, Y, Zhen, J, Yu, H, Liu, T, Gu, X, Liu, H, Ma, W, Shang, X, Bai, Y, Liu, W, Rooney, C, Smith, A, Lopes, S, Demarzo, M, do Patrocínio Nunes, M, Lorenz, P, Gründemann, C, Heinrich, M, Garcia-Käufer, M, Grunewald, F, Messerschmidt, S, Herrick, A, Gruber, K, Knödler, M, Steinborn, C, Lu, T, Wang, L, Wu, D, Luberto, CM, Hall, DL, Chad-Friedman, E, Lechner, S, Park, ER, Park, E, Goodman, J, Luer, S, Heri, M, von Ammon, K, Landini, I, Lapucci, A, Nobili, S, Mini, E, McDermott, C, Richards, S, Cox, D, Frossell, S, Leydon, G, Eyles, C, Raphael, H, Rogers, R, Selby, M, Adler, C, Allam, J, Bu, X, Zhang, H, Zhang, J, Mikolasek, M, Berg, J, Witt, C, Barth, J, Miskulin, I, Lalic, Z, Miskulin, M, Dumic, A, Sebo, D, Vcev, A, Mohammed, NAA, Im, HB, Mukherjee, A, Kandhare, A, Bodhankar, S, Thakurdesai, P, Munk, N, Evans, E, Froman, A, Kline, M, Bair, MJ, Musial, F, Alræk, T, Hamre, HJ, Björkman, L, Fønnebø, VM, Ni, Q, Tong, X-L, Li, X-L, Liu, W-K, Feng, S, Zhao, X-Y, Zheng, Y-J, Zhao, X-M, Lin, Y-Q, Zhao, T-Y, Phd, HC, Liu, F, Zhao, L-H, Ye, R, Gu, C-J, Peng, W, De Carvalho, D, El-Bayoumi, M, Haig, B, Kelly, K, Wade, DJ, Portalupi, E, Gobo, G, Bellavita, L, Guglielmetti, C, Raak, C, Teuber, M, Molsberger, F, von Rath, U, Reichelt, U, Schwanebeck, U, Zeil, S, Vogelberg, C, Veintimilla, DR, Mery, GT, Villavicencio, MM, Moran, SH, Sachse, C, Gündlin, PW, Sahebkarkhorasani, M, Azizi, H, Schumann, D, Sundberg, T, Leach, MJ, Seca, S, Greten, H, Selliah, S, Shakya, A, Sherbakova, A, Ulrich-Merzenich, G, Abdel-Aziz, H, Sibinga, E, Webb, L, Ellen, J, Skrautvol, K, Nåden, D, Song, R, Grabowska, W, Osypiuk, K, Diaz, GV, Bonato, P, Park, M, Hausdorff, J, Fox, M, Sudarsky, LR, Tarsy, D, Novakowski, J, Macklin, EA, Wayne, PM, Hwang, I, Ahn, S, Lee, M-A, Sohn, MK, Sorokin, O, Heydeck, D, Borchert, A, Hohmann, C-D, Kühn, H, Kirschbaum, C, Stalder, T, Stöckigt, B, Teut, M, Suhr, R, Sulmann, D, Streeter, C, Gerbarg, P, Silveri, M, Brown, R, Jensen, J, Rutert, B, Eggert, A, Längler, A, Holmberg, C, Sun, J, Deng, X, Li, W-Y, Wen, B, Robinson, N, Liu, J-P, Sung, HK, Yang, N, Shin, SM, Jung, H, Kim, YJ, Jung, WS, Park, TY, Suzuki, K, Ito, T, Uchida, S, Kamohara, S, Ono, N, Takamura, M, Yokochi, A, Maruyama, K, Tapia, P, Thabaut, K, Thronicke, A, Steele, M, Matthes, H, Herbstreit, C, Schad, F, Tian, J, Yang, L, Tian, T, Tian, X, Wang, C, Chai, QY, Zhang, L, Xia, R, Huang, N, Fei, Y, Liu, J, Trent, N, Miraglia, M, Dusek, J, Pasalis, E, Khalsa, SB, Trifunovic-König, M, Koch, A, Uebelacker, L, Tremont, G, Gillette, L, Epstein-Lubow, G, Strong, D, Abrantes, A, Tyrka, A, Tran, T, Gaudiano, B, Miller, I, Ullmann, G, Li, Y, Vaidya, S, Marathe, V, Vale, AC, Motta, J, Donadão, F, Valente, AC, Valente, LCC, Ghelman, R, Vesovic, D, Jevdic, D, Jevdic, A, Jevdic, K, Djacic, M, Letic, D, Bozic, D, Markovic, M, Dunjic, S, Ruscuklic, G, Baksa, D, Vrca, K, Vincent, A, Wahner-Roedler, D, Whipple, M, Vogelius, MM, Friesecke, I, Gündling, PW, Mahapatra, S, Hynes, R, Van Rooy, K, Looker, S, Ghosh, A, Bauer, B, Cutshall, S, Walach, H, Flores, AB, Ofner, M, Kastner, A, Schwarzl, G, Schwameder, H, Alexander, N, Strutzenberger, G, Wang, S, Shi, J, Hao, Y, Wu, J, Qiu, Z, Wang, Y-H, Lou, C-J, Watts, S, Wayne, P, Vergara-Diaz, G, Gow, B, Miranda, J, Sudarsky, L, Macklin, E, Wode, K, Bergqvist, J, Bernhardsson, B-M, Nordberg, JH, Sharp, L, Henriksson, R, Woo, Y, Hyun, MK, Wu, H, Wang, T-F, Zhao, Y, Wei, Y, Tian, L, Wang, X, Wu, R, Han, M, Caldwell, PHY, Liu, S, Chai, Q, Guo, Z, Liu, Z, Yang, IJ, Lincha, VR, Ahn, SH, Lee, DU, Shin, HM, Sung, H, Kim, Y, Yap, A, Kwan, YH, Tan, CS, Ibrahim, S, Ang, SB, Yayi, A, Yoo, JE, Yoo, HR, Jang, SB, Lee, HL, Youssef, A, Ezzat, S, Motaal, AA, El-Askary, H, Yu, X, Cui, Y, Yun, Y, Ahn, J-H, Jang, B-H, Kim, K-S, Choi, I, Glinz, A, ten Brink, F, Büssing, A, Gutenbrunner, C, Helbrecht, B, Fang, T, Shen, Z, Zhang, R, Wu, F, Li, M, Xuan, X, Shen, X, Ren, K, Berman, B, Zheng, Z, Wan, Y, Ma, X, Dong, F, Zick, S, Harris, R, Bae, GE, Kwon, JN, Lee, HY, Nam, JK, Lee, SD, Lee, DH, Han, JY, Yun, YJ, Lee, JH, Park, HL, Park, SH, Bocci, C, Ivaldi, GB, Vietti, I, Meaglia, I, Guffi, M, Ruggiero, R, Gualea, M, Longa, E, Bonucci, M, Croke, S, Rodriguez, LD, Caracuel-Martínez, JC, Fajardo-Rodríguez, MF, Ariza-García, A, la Fuente, FG-D, Arroyo-Morales, M, Estrems, MS, Gómez, VG, Sabater, MV, Ferreri, R, Bernardini, S, Pulcri, R, Cracolici, F, Rinaldi, M, Porciani, C, Fisher, P, Hughes, J, Mendoza, A, MacPherson, H, Filshie, J, Di Francesco, A, Bernardini, A, Messe, M, Primitivo, V, Iasella, PA, Taminato, M, Alcantara, JDC, De Oliveira, KR, Rodrigues, DCDA, Mumme, JRC, Sunakozawa, OKM, Filho, VO, Goldenberg, J, Day, A, Sasagawa, M, Ward, L, Cooley, K, Gunnarsdottir, T, Hjaltadottir, I, Hajimonfarednejad, M, Hannan, N, Hellsing, R, Andermo, S, Arman, M, von Hörsten, I, Torrielo, PV, Vilaró, CLA, Cabrera, FC, Hui, H, Ziea, E, Tsui, D, Hsieh, J, Lam, C, Chan, E, Jensen, MP, Battalio, SL, Chan, J, Edwards, KA, Gertz, KJ, Day, MA, Sherlin, LH, Ehde, DM, Börner, A, Lee, B, Chang, GT, Menassa, A, Motoo, Y, Müller, J, Rabini, S, Vinson, B, Storr, M, Niemeijer, M, Hoekman, J, Ruijssenaaars, W, Njoku, FC, Norheim, AJ, Okumus, F, Oncu-Celik, H, Ee, C, Thuraisingam, S, Pirotta, M, French, S, Xue, C, Teede, H, Kristoffersen, AE, Sirois, F, Stub, T, Engler, J, Joos, S, Güthlin, C, Felenda, J, Beckmann, C, Stintzing, F, Evans, R, Bronfort, G, Keefe, D, Taberko, A, Hanson, L, Haley, A, Ma, H, Jolton, J, Yarosh, L, Keefe, F, Nam, J, Ojala, L, Kreitzer, MJ, Fink, C, Kraft, K, Flower, A, Lewith, G, Harman, K, Stuart, B, Bishop, FL, Frawley, J, Füleki, L, Kiss, E, Vancsik, T, Krenacs, T, Funabashi, M, Pohlman, KA, Mior, S, Thiel, H, Hill, MD, Cassidy, DJ, Westaway, M, Yager, J, Hurwitz, E, Kawchuk, GN, O’Beirne, M, Vohra, S, Gaboury, I, Morin, C, Gaertner, K, Torchetti, L, Frei-Erb, M, Kundi, M, Frass, M, Gallo, E, Maggini, V, Comite, M, Sofi, F, Baccetti, S, Vannacci, A, Di Stefano, M, Monechi, MV, Gori, L, Rossi, E, Firenzuoli, F, Mediati, RD, Ballerini, G, Gardiner, P, Lestoquoy, AS, Negash, L, Stillman, S, Shah, P, Liebschutz, J, Adelstein, P, Farrell-Riley, C, Brackup, I, Penti, B, Saper, R, Sampedro, IG, Carvajal, G, Gleiss, A, Gross, MM, Brendlin, D, Röttger, J, Stritter, W, Seifert, G, Grzanna, N, Stange, R, Guendling, PW, Gu, W, Lu, Y, Wang, J, Zhang, C, Bai, H, He, Y, Zhang, X, Zhang, Z, Wang, D, Meng, F, Hagel, A, Albrecht, H, Vollbracht, C, Dauth, W, Hagel, W, Vitali, F, Ganzleben, I, Schultis, H, Konturek, P, Stein, J, Neurath, M, Raithel, M, Krick, B, Haller, H, Klose, P, Dobos, G, Kümmel, S, Cramer, H, Saha, FJ, Kowoll, A, Ebner, B, Berger, B, Choi, K-E, He, L, Wang, H, He, X, Gu, C, Zhang, Y, Zhao, L, Tong, X, Ho, RST, Chung, VCH, Wu, X, Wong, CHL, Wu, JCY, Wong, SYS, Lau, AYL, Sit, RWS, Wong, W, Holmes, M, Bishop, F, Calman, L, Newell, D, Field, J, Htut, WL, Han, D, Choi, DI, Choi, SJ, Kim, HY, Hwang, JH, Huang, CW, Jang, BH, Chen, FP, Ko, SG, Huang, W, Jin, D, Lian, F, Jang, S, Kim, KH, Lee, EK, Sun, SH, Go, HY, Ko, Y, Park, S, Shin, YC, Janik, H, Greiffenhagen, N, Bolte, J, Jaworski, M, Adamus, M, Dobrzynska, A, Jeitler, M, Jaspers, J, von Scheidt, C, Koch, B, Michalsen, A, Steckhan, N, Kessler, C, Huang, W-J, Pang, B, Lian, F-M, Jong, M, Baars, E, Glockmann, A, Hamre, H, Kainuma, M, Murakami, A, Kubota, T, Kobayashi, D, Sumoto, Y, Furusyo, N, Ando, S-I, Shimazoe, T, Kelber, O, Verjee, S, Gorgus, E, Schrenk, D, Kemper, K, Hill, E, Rao, N, Gascon, G, Mahan, J, Kienle, G, Dietrich, J, Schmoor, C, Huber, R, Kim, WH, Ahmed, M, Meggyeshazi, N, Kovago, C, Klaus, AK, Zerm, R, Pranga, D, Ostermann, T, Reif, M, von Laue, HB, Brinkhaus, B, Kröz, M, Recchia, DR, Klein-Laansma, CT, von Hagens, C, Jansen, JP, van Wietmarschen, H, Jong, MC, Sun, S-H, Go, H-Y, Jeon, C-Y, Song, Y-K, Ko, S-G, Koch, AK, Rabsilber, S, Lauche, R, Langhorst, J, Trifunovic-Koenig, M, Koster, E, Delnoij, D, Kroll, L, Weiss, K, Kubo, A, Hendlish, S, Altschuler, A, Connolly, N, Avins, A, Wardle, J, Lee, D, Sibbritt, D, Adams, J, Park, C, Mishra, G, Lechner, J, Lee, I, Chae, Y, Lee, J, Cho, SH, Choi, Y, Lee, JY, Ryu, HS, Yoon, SS, Oh, HK, Hyun, LK, Kim, JO, Yoon, SW, Lee, J-Y, Shin, S-H, Jang, M, Müller, I, Park, S-HJ, Laird, L, Mitchell, S, Li, X, Wang, Y, Zhen, J, Yu, H, Liu, T, Gu, X, Liu, H, Ma, W, Shang, X, Bai, Y, Liu, W, Rooney, C, Smith, A, Lopes, S, Demarzo, M, do Patrocínio Nunes, M, Lorenz, P, Gründemann, C, Heinrich, M, Garcia-Käufer, M, Grunewald, F, Messerschmidt, S, Herrick, A, Gruber, K, Knödler, M, Steinborn, C, Lu, T, Wang, L, Wu, D, Luberto, CM, Hall, DL, Chad-Friedman, E, Lechner, S, Park, ER, Park, E, Goodman, J, Luer, S, Heri, M, von Ammon, K, Landini, I, Lapucci, A, Nobili, S, Mini, E, McDermott, C, Richards, S, Cox, D, Frossell, S, Leydon, G, Eyles, C, Raphael, H, Rogers, R, Selby, M, Adler, C, Allam, J, Bu, X, Zhang, H, Zhang, J, Mikolasek, M, Berg, J, Witt, C, Barth, J, Miskulin, I, Lalic, Z, Miskulin, M, Dumic, A, Sebo, D, Vcev, A, Mohammed, NAA, Im, HB, Mukherjee, A, Kandhare, A, Bodhankar, S, Thakurdesai, P, Munk, N, Evans, E, Froman, A, Kline, M, Bair, MJ, Musial, F, Alræk, T, Hamre, HJ, Björkman, L, Fønnebø, VM, Ni, Q, Tong, X-L, Li, X-L, Liu, W-K, Feng, S, Zhao, X-Y, Zheng, Y-J, Zhao, X-M, Lin, Y-Q, Zhao, T-Y, Phd, HC, Liu, F, Zhao, L-H, Ye, R, Gu, C-J, Peng, W, De Carvalho, D, El-Bayoumi, M, Haig, B, Kelly, K, Wade, DJ, Portalupi, E, Gobo, G, Bellavita, L, Guglielmetti, C, Raak, C, Teuber, M, Molsberger, F, von Rath, U, Reichelt, U, Schwanebeck, U, Zeil, S, Vogelberg, C, Veintimilla, DR, Mery, GT, Villavicencio, MM, Moran, SH, Sachse, C, Gündlin, PW, Sahebkarkhorasani, M, Azizi, H, Schumann, D, Sundberg, T, Leach, MJ, Seca, S, Greten, H, Selliah, S, Shakya, A, Sherbakova, A, Ulrich-Merzenich, G, Abdel-Aziz, H, Sibinga, E, Webb, L, Ellen, J, Skrautvol, K, Nåden, D, Song, R, Grabowska, W, Osypiuk, K, Diaz, GV, Bonato, P, Park, M, Hausdorff, J, Fox, M, Sudarsky, LR, Tarsy, D, Novakowski, J, Macklin, EA, Wayne, PM, Hwang, I, Ahn, S, Lee, M-A, Sohn, MK, Sorokin, O, Heydeck, D, Borchert, A, Hohmann, C-D, Kühn, H, Kirschbaum, C, Stalder, T, Stöckigt, B, Teut, M, Suhr, R, Sulmann, D, Streeter, C, Gerbarg, P, Silveri, M, Brown, R, Jensen, J, Rutert, B, Eggert, A, Längler, A, Holmberg, C, Sun, J, Deng, X, Li, W-Y, Wen, B, Robinson, N, Liu, J-P, Sung, HK, Yang, N, Shin, SM, Jung, H, Kim, YJ, Jung, WS, Park, TY, Suzuki, K, Ito, T, Uchida, S, Kamohara, S, Ono, N, Takamura, M, Yokochi, A, Maruyama, K, Tapia, P, Thabaut, K, Thronicke, A, Steele, M, Matthes, H, Herbstreit, C, Schad, F, Tian, J, Yang, L, Tian, T, Tian, X, Wang, C, Chai, QY, Zhang, L, Xia, R, Huang, N, Fei, Y, Liu, J, Trent, N, Miraglia, M, Dusek, J, Pasalis, E, Khalsa, SB, Trifunovic-König, M, Koch, A, Uebelacker, L, Tremont, G, Gillette, L, Epstein-Lubow, G, Strong, D, Abrantes, A, Tyrka, A, Tran, T, Gaudiano, B, Miller, I, Ullmann, G, Li, Y, Vaidya, S, Marathe, V, Vale, AC, Motta, J, Donadão, F, Valente, AC, Valente, LCC, Ghelman, R, Vesovic, D, Jevdic, D, Jevdic, A, Jevdic, K, Djacic, M, Letic, D, Bozic, D, Markovic, M, Dunjic, S, Ruscuklic, G, Baksa, D, Vrca, K, Vincent, A, Wahner-Roedler, D, Whipple, M, Vogelius, MM, Friesecke, I, Gündling, PW, Mahapatra, S, Hynes, R, Van Rooy, K, Looker, S, Ghosh, A, Bauer, B, Cutshall, S, Walach, H, Flores, AB, Ofner, M, Kastner, A, Schwarzl, G, Schwameder, H, Alexander, N, Strutzenberger, G, Wang, S, Shi, J, Hao, Y, Wu, J, Qiu, Z, Wang, Y-H, Lou, C-J, Watts, S, Wayne, P, Vergara-Diaz, G, Gow, B, Miranda, J, Sudarsky, L, Macklin, E, Wode, K, Bergqvist, J, Bernhardsson, B-M, Nordberg, JH, Sharp, L, Henriksson, R, Woo, Y, Hyun, MK, Wu, H, Wang, T-F, Zhao, Y, Wei, Y, Tian, L, Wang, X, Wu, R, Han, M, Caldwell, PHY, Liu, S, Chai, Q, Guo, Z, Liu, Z, Yang, IJ, Lincha, VR, Ahn, SH, Lee, DU, Shin, HM, Sung, H, Kim, Y, Yap, A, Kwan, YH, Tan, CS, Ibrahim, S, Ang, SB, Yayi, A, Yoo, JE, Yoo, HR, Jang, SB, Lee, HL, Youssef, A, Ezzat, S, Motaal, AA, El-Askary, H, Yu, X, Cui, Y, Yun, Y, Ahn, J-H, Jang, B-H, Kim, K-S, Choi, I, Glinz, A, ten Brink, F, Büssing, A, Gutenbrunner, C, Helbrecht, B, Fang, T, Shen, Z, Zhang, R, Wu, F, Li, M, Xuan, X, Shen, X, Ren, K, Berman, B, Zheng, Z, Wan, Y, Ma, X, Dong, F, Zick, S, Harris, R, Bae, GE, Kwon, JN, Lee, HY, Nam, JK, Lee, SD, Lee, DH, Han, JY, Yun, YJ, Lee, JH, Park, HL, Park, SH, Bocci, C, Ivaldi, GB, Vietti, I, Meaglia, I, Guffi, M, Ruggiero, R, Gualea, M, Longa, E, Bonucci, M, Croke, S, Rodriguez, LD, Caracuel-Martínez, JC, Fajardo-Rodríguez, MF, Ariza-García, A, la Fuente, FG-D, Arroyo-Morales, M, Estrems, MS, Gómez, VG, Sabater, MV, Ferreri, R, Bernardini, S, Pulcri, R, Cracolici, F, Rinaldi, M, Porciani, C, Fisher, P, Hughes, J, Mendoza, A, MacPherson, H, Filshie, J, Di Francesco, A, Bernardini, A, Messe, M, Primitivo, V, Iasella, PA, Taminato, M, Alcantara, JDC, De Oliveira, KR, Rodrigues, DCDA, Mumme, JRC, Sunakozawa, OKM, Filho, VO, Goldenberg, J, Day, A, Sasagawa, M, Ward, L, Cooley, K, Gunnarsdottir, T, Hjaltadottir, I, Hajimonfarednejad, M, Hannan, N, Hellsing, R, Andermo, S, Arman, M, von Hörsten, I, Torrielo, PV, Vilaró, CLA, Cabrera, FC, Hui, H, Ziea, E, Tsui, D, Hsieh, J, Lam, C, Chan, E, Jensen, MP, Battalio, SL, Chan, J, Edwards, KA, Gertz, KJ, Day, MA, Sherlin, LH, Ehde, DM, Börner, A, Lee, B, Chang, GT, Menassa, A, Motoo, Y, Müller, J, Rabini, S, Vinson, B, Storr, M, Niemeijer, M, Hoekman, J, Ruijssenaaars, W, Njoku, FC, Norheim, AJ, Okumus, F, and Oncu-Celik, H

Published
2017

34. Abnormal plasma DNA profiles in early ovarian cancer using a non-invasive prenatal testing platform: implications for cancer screening

Author

Cohen, PA, Flowers, N, Tong, S, Hannan, N, Pertile, MD, Hui, L, Cohen, PA, Flowers, N, Tong, S, Hannan, N, Pertile, MD, and Hui, L

Abstract

BACKGROUND: Non-invasive prenatal testing (NIPT) identifies fetal aneuploidy by sequencing cell-free DNA in the maternal plasma. Pre-symptomatic maternal malignancies have been incidentally detected during NIPT based on abnormal genomic profiles. This low coverage sequencing approach could have potential for ovarian cancer screening in the non-pregnant population. Our objective was to investigate whether plasma DNA sequencing with a clinical whole genome NIPT platform can detect early- and late-stage high-grade serous ovarian carcinomas (HGSOC). METHODS: This is a case control study of prospectively-collected biobank samples comprising preoperative plasma from 32 women with HGSOC (16 'early cancer' (FIGO I-II) and 16 'advanced cancer' (FIGO III-IV)) and 32 benign controls. Plasma DNA from cases and controls were sequenced using a commercial NIPT platform and chromosome dosage measured. Sequencing data were blindly analyzed with two methods: (1) Subchromosomal changes were called using an open source algorithm WISECONDOR (WIthin-SamplE COpy Number aberration DetectOR). Genomic gains or losses ≥ 15 Mb were prespecified as "screen positive" calls, and mapped to recurrent copy number variations reported in an ovarian cancer genome atlas. (2) Selected whole chromosome gains or losses were reported using the routine NIPT pipeline for fetal aneuploidy. RESULTS: We detected 13/32 cancer cases using the subchromosomal analysis (sensitivity 40.6 %, 95 % CI, 23.7-59.4 %), including 6/16 early and 7/16 advanced HGSOC cases. Two of 32 benign controls had subchromosomal gains ≥ 15 Mb (specificity 93.8 %, 95 % CI, 79.2-99.2 %). Twelve of the 13 true positive cancer cases exhibited specific recurrent changes reported in HGSOC tumors. The NIPT pipeline resulted in one "monosomy 18" call from the cancer group, and two "monosomy X" calls in the controls. CONCLUSIONS: Low coverage plasma DNA sequencing used for prenatal testing detected 40.6 % of all HGSOC, including 38 % of early stag

Published
2016

36. Generation of Bioengineered Biliary Tissue Using Primary in Vitro Propagated Extra-Hepatic Cholangiocytes and Biodegradable Scaffolds

Author

Sampaziotis, F., primary, de Brito, M.C., additional, Sawiak, S., additional, Godfrey, E., additional, Ortmann, D., additional, Bertero, A., additional, Upponi, S., additional, Pawlowski, M., additional, Georgakopoulos, N., additional, Bargehr, J., additional, Hannan, N., additional, Gelson, W., additional, Alexander, G., additional, Saeb-Parsy, K., additional, and Vallier, L., additional

Published
2016
Full Text
View/download PDF

42. Abstracts of the 26th World Congress on Ultrasound in Obstetrics and Gynecology, Rome, Italy, 24-28 September 2016.

Author

Cohen, P., Flowers, N., Pertile, M.D., Hannan, N., Tong, S., and Hui, L.

Subjects
EARLY detection of cancer, OVARIAN cancer, PRENATAL diagnosis
Abstract

An abstract of the article "Detection rates of high grade serous ovarian cancers using a clinical non-invasive prenatal testing platform: potential for ovarian cancer screening" by P. Cohen and colleagues is presented.

Published
2016
Full Text
View/download PDF

43. Immersed in a reservoir of potential: amniotic fluid-derived extracellular vesicles.

Author

Atukorala I, Hannan N, and Hui L

Subjects
Animals, Humans, Female, Pregnancy, Amniotic Fluid, Knowledge, Extracellular Vesicles, Mesenchymal Stem Cells
Abstract

This review aims to encapsulate the current knowledge in extracellular vesicles extracted from amniotic fluid and amniotic fluid derived stem/stromal cells. Amniotic fluid (AF) bathes the developing fetus, providing nutrients and protection from biological and mechanical dangers. In addition to containing a myriad of proteins, immunoglobulins and growth factors, AF is a rich source of extracellular vesicles (EVs). These vesicles originate from cells in the fetoplacental unit. They are biological messengers carrying an active cargo enveloped within the lipid bilayer. EVs in reproduction are known to play key roles in all stages of pregnancy, starting from fertilisation through to parturition. The intriguing biology of AF-derived EVs (AF-EVs) in pregnancy and their untapped potential as biomarkers is currently gaining attention. EV studies in numerous animal and human disease models have raised expectations of their utility as therapeutics. Amniotic fluid stem cell and mesenchymal stromal cell-derived EVs (AFSC-EVs) provide an established supply of laboratory-made EVs. This cell-free mode of therapy is popular as an alternative to stem cell therapy, revealing similar, if not better therapeutic outcomes. Research has demonstrated the successful application of AF-EVs and AFSC-EVs in therapy, harnessing their anti-inflammatory, angiogenic and regenerative properties. This review provides an overview of such studies and discusses concerns in this emerging field of research., (© 2024. The Author(s).)

Published
2024
Full Text
View/download PDF

44. Development of a sandwich ELISA to detect circulating, soluble IRAP as a potential disease biomarker.

Author

Vear A, Thalmann C, Youngs K, Hannan N, Gaspari T, and Chai SY

Subjects
Humans, Female, Pregnancy, Enzyme-Linked Immunosorbent Assay, Antibodies, Blotting, Western, Cystinyl Aminopeptidase metabolism, Aminopeptidases, Insulin
Abstract

There is growing interest in the use of the enzyme, insulin regulated aminopeptidase (IRAP), as a biomarker for conditions such as cardio-metabolic diseases and ischemic stroke, with upregulation in its tissue expression in these conditions. However, quantification of circulating IRAP has been hampered by difficulties in detecting release of the truncated, soluble form of this enzyme into the blood stream. The current study aimed to develop a sandwich ELISA using novel antibodies directed towards the soluble portion of IRAP (sIRAP), to improve accuracy in detection and quantification of low levels of sIRAP in plasma. A series of novel anti-IRAP antibodies were developed and found to be highly specific for sIRAP in Western blots. A sandwich ELISA was then optimised using two distinct antibody combinations to detect sIRAP in the low nanogram range (16-500 ng/ml) with a sensitivity of 9 ng/ml and intra-assay variability < 10%. Importantly, the clinical validity of the ELISA was verified by the detection of significant increases in the levels of sIRAP throughout gestation in plasma samples from pregnant women. The specific and sensitive sandwich ELISA described in this study has the potential to advance the development of IRAP as a biomarker for certain diseases., (© 2023. Crown.)

Published
2023
Full Text
View/download PDF

45. Burnout in mental health services in Ireland during the COVID-19 pandemic.

Author

Adamis D, Minihan E, Hannan N, Doherty AM, and McNicholas F

Abstract

Background: Burnout is a consequence of chronic occupational stress. Specific work-related factors may contribute to burnout experienced by those working in mental health services (MHS), many of which have increased since the COVID-19 pandemic., Aims: To examine personal, work- and patient-related burnout among MHS staff in Ireland during the COVID-19 pandemic, and explore the impact of work-related conditions on burnout., Method: We conducted a cross-sectional survey of three MHS across Ireland utilising a study-specific questionnaire, the Copenhagen Burnout Inventory and the Effort-Reward Imbalance scale., Results: Of 396 participants, 270 (70.6%) were female. Moderate and high personal burnout was experienced by 244 (64.1%) participants; work-related burnout by 231 (58.5%) participants and patient-related burnout by 83 (21.5%) participants. Risk factors for both personal and work-related burnout were female gender, urban service, time spent outside main responsibilities, overcommitment, high score on the Effort-Reward Imbalance scale and intention to change job. Being younger, with high workload and deterioration of personal mental health during the pandemic was associated with higher personal burnout, whereas a lack of opportunity to talk about work-related stress contributed to work-related burnout. Fewer factors were associated with patient-related burnout, namely overcommitment, working in urban services and poorer physical and mental health during the COVID-19 pandemic., Conclusions: High levels of personal and work-related burnout were found among mental health workers. The weak association with COVID-19-related factors suggest levels of burnout predated the pandemic. This has implications for MHS given the recognised additional work burden created by COVID-19.

Published
2023
Full Text
View/download PDF

46. Nosocomial Infection Among Burn Patients Admitted to a Tertiary Care Hospital of Bangladesh: A Cross-Sectional Study.

Author

Dey PK, Galib A, Sardar A, Islam MT, Sharif HMZ, Zaman F, Hannan N, and Rafi MA

Abstract

Nosocomial infection is a major challenge for the appropriate management of burns. The present study aimed to investigate incidence, risk factors, and causative organisms of nosocomial infection in burn patients of Khulna, Bangladesh. This cross-sectional study was conducted among patients admitted to the Burn and Plastic Surgery Department of Khulna Medical College Hospital (KMCH) from January to December 2020. Relevant data were collected from the patients' hospital records. Samples of wound swabs and blood were collected and cultured in the microbiology laboratory of KMCH. Logistic regression models were used to determine risk factors for infective complications in burn patients. All statistical analyses were carried out using SPSS version 26.0. A total of 100 burn patients were included. Mean age was 29.2 years with a male-female ratio of 1.3:1. Flame burns were most prevalent among the patients (41%), followed by scald (23%) and electric burns (15%). Almost 40% patients had full thickness burn. The incidence of nosocomial infection was 42% (wound infection 33% and septicemia 9%). Total body surface area of burn >40% (OR 7.56, 95% CI 2.89-19.81), full thickness burn (OR 34.40, 95% CI 3.25-97.14) and prolonged hospital stay (aOR 1.31, 95% CI 1.15-1.51) were significant risk factors for nosocomial infection. Staphylococcus aureus was the most commonly isolated organism (45%), followed by Streptococcus (24%), Pseudomonas aeruginosa (19%) and Escherichia coli (12%). As the epidemiology of nosocomial infection is not the same in different health facilities, a facility-based comprehensive burn management protocol considering the local epidemiology and causative organisms of burn wound infection is crucial for the prevention and management of nosocomial infections in burn patients., (© 2023 Euro-Mediterranean Council for Burns and Fire Disasters.)

Published
2023

47. SLC38A4 Amino Acid Transporter Expression Is Significantly Lower in Early Preterm Intrauterine Growth Restriction Complicated Placentas.

Author

Kadife E, Harper A, De Alwis N, Chien K, Hannan N, and Brownfoot FC

Subjects
Infant, Newborn, Pregnancy, Female, Humans, Fetal Growth Retardation genetics, Fetal Growth Retardation metabolism, Trophoblasts metabolism, Amino Acid Transport Systems genetics, Amino Acid Transport Systems metabolism, Hypoxia genetics, Hypoxia metabolism, Amino Acid Transport System A genetics, Amino Acid Transport System A metabolism, Placenta metabolism, Pre-Eclampsia genetics, Pre-Eclampsia metabolism
Abstract

Intrauterine growth restriction (IUGR), predominantly caused by placental insufficiency, affects partitioning of nutrients to the fetus. The system A sodium-coupled transporters (SNAT or SLC38), of types A1, A2, and A4, control non-essential amino acid uptake and supply. Here, we aimed to investigate the expression of these transporters across different placental disease cohorts and cells. To determine disease impact, transporter expressions at the gene (qPCR) and protein (western blots) level were assessed in gestationally matched placental tissues. Early (<34 weeks), and late (34−36 weeks) onset IUGR cases with/out preeclampsia were compared to preterm controls. We also investigated level of transporter expression in primary trophoblasts under glucose deprivation (n = 6) and hypoxia conditions (n = 7). SLC38A4 protein was significantly downregulated in early preterm pregnancies complicated with IUGR with/out preeclampsia. There were no differences in late preterm IUGR cohorts. Furthermore, we demonstrate for the first time in primary trophoblast cells, that gene expression of the transporters was sensitive to and induced by glucose starvation. SLC38A4 mRNA expression was also significantly upregulated in response to hypoxia. Thus, SLC38A4 expression was persistently low in early preterm IUGR pregnancies, regardless of disease aetiology. This suggests that gestational age at delivery, and consequently IUGR severity, may influence loss of its expression., Competing Interests: The authors declare no conflict of interest.

Published
2022
Full Text
View/download PDF

48. Hydroxychloroquine reduces soluble Flt-1 secretion from human cytotrophoblast, but does not mitigate markers of endothelial dysfunction in vitro.

Author

Kadife E, Hannan N, Harper A, Binder N, Beard S, and Brownfoot FC

Subjects
Female, Humans, Pregnancy, Trophoblasts metabolism, Placenta Growth Factor metabolism, Placenta metabolism, Endothelial Cells metabolism, Hydroxychloroquine therapeutic use, Vascular Endothelial Growth Factor A metabolism, Endoglin metabolism, Biomarkers metabolism, Inflammation metabolism, Pre-Eclampsia drug therapy, Pre-Eclampsia metabolism, Vascular Diseases metabolism
Abstract

Preeclampsia is a multi-system disease that can have severe, even fatal implications for the mother and fetus. Abnormal placentation can lead to ischaemic tissue injury and placental inflammation. In turn, the placenta releases anti-angiogenic factors into the maternal circulation. These systemically act to neutralise angiogenic factors causing endothelial dysfunction causing preeclampsia. Hydroxychloroquine is an immune modulating drug that is considered safe in pregnancy. There is epidemiological evidence suggesting it may reduce the risk of preeclampsia. Here, we examined the effects hydroxychloroquine on the production and secretion of sFlt-1, soluble endoglin (sENG), placental growth factor (PlGF) and vascular endothelial growth factor (VEGF) in primary human placenta, cytotrophoblasts and umbilical vein endothelial cells (endothelial cell model). Hydroxychloroquine treatment decreased mRNA expression of two sFlt-1 isoforms and its protein secretion. sENG was not reduced. Hydroxychloroquine treatment increased secretion of pro-angiogenic factor PIGF from endothelial cells. It did not significantly reduce the expression of the endothelial cell inflammation marker, ET-1, and inflammation induced expression of the adhesion molecule, VCAM. Hydroxychloroquine could not overcome leukocyte adhesion to endothelial cells. Hydroxychloroquine mitigates features of preeclampsia, but it does not reduce key markers of endothelial dysfunction., Competing Interests: The authors have declared that no competing interests exist., (Copyright: © 2022 Kadife et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)

Published
2022
Full Text
View/download PDF

49. Pravastatin, proton-pump inhibitors, metformin, micronutrients, and biologics: new horizons for the prevention or treatment of preeclampsia.

Author

Tong S, Kaitu'u-Lino TJ, Hastie R, Brownfoot F, Cluver C, and Hannan N

Subjects
Antibodies, Monoclonal therapeutic use, Antioxidants therapeutic use, Antithrombin III therapeutic use, Biological Products therapeutic use, Blood Component Removal, Female, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Hypoglycemic Agents therapeutic use, Metformin therapeutic use, Micronutrients therapeutic use, Placenta Growth Factor therapeutic use, Plant Extracts therapeutic use, Pravastatin therapeutic use, Pregnancy, Proton Pump Inhibitors therapeutic use, RNA, Small Interfering, Recombinant Proteins therapeutic use, Sulfasalazine therapeutic use, Vascular Endothelial Growth Factor Receptor-1 blood, Pre-Eclampsia prevention & control
Abstract

There has been increasing research momentum to identify new therapeutic agents for the prevention or treatment of preeclampsia, drugs that can affect the underlying disease pathophysiology. Molecular targets of candidate treatments include oxidative stress, antiangiogenic factors, and the angiotensin, nitric oxide, and proinflammatory pathways. The proposed treatments undergoing preclinical and clinical trial evaluation are thought to act on placental or endothelial disease or both. Most have adopted the pragmatic strategy of repurposing drugs. Of all the therapeutic agents proposed, pravastatin has received the most interest. There are preclinical studies showing that it has pleiotropic actions that favorably impact on multiple molecular targets and can resolve a preeclampsia phenotype in many animal models. An early phase clinical trial suggests that it may have therapeutic activity. Several large prevention trials are planned or ongoing and, when completed, could definitively address whether pravastatin can prevent preeclampsia. Proton-pump inhibitors, metformin, and sulfasalazine are other drugs with preclinical evidence of multiple molecular actions that could resolve the pathophysiology of preeclampsia. These agents are also currently being evaluated in clinical trials. There have been many recent preclinical studies identifying the potential of numerous natural compounds to treat preeclampsia, such as plant extracts and micronutrients that have potent anti-inflammatory or antioxidant activity. Recent preclinical studies have also proposed novel molecular-targeted strategies, such as monoclonal antibodies targeting tumor necrosis factor alpha, placental growth factor, and short interfering RNA technology, to silence the gene expression of soluble fms-like tyrosine kinase-1 or angiotensinogen. Other treatment approaches that have transitioned to human trials (ranging from single-arm to phase III trials that have been completed or are ongoing) include folic acid, nitric oxide donors (such as L-arginine), recombinant antithrombin III, digoxin immune antigen-binding fragment, and melatonin. There have been case series showing the removal of circulating soluble fms-like tyrosine kinase-1 may help stabilize the disease and prolong pregnancy. Interestingly, there are case reports suggesting that monoclonal antibody eculizumab (complement inhibitor) may have therapeutic potential. If new agents are discovered that are proven to be effective in preventing or treating preeclampsia, the potential to improve global maternal and perinatal health will be significant., (Crown Copyright © 2020. Published by Elsevier Inc. All rights reserved.)

Published
2022
Full Text
View/download PDF

50. What influences complementary medicine use for children with eosinophilic esophagitis? Findings from a cross-sectional survey.

Author

Hannan N, Steel A, Tiralongo E, and McMillan SS

Subjects
Australia, Child, Cross-Sectional Studies, Humans, Surveys and Questionnaires, Complementary Therapies, Eosinophilic Esophagitis drug therapy
Abstract

Background and Purpose: Utilization of complementary medicines (CMs) amongst children with eosinophilic esophagitis (EoE) in Australia is high. Carers' beliefs, perceptions and use of CM can influence the decision to use CM in children in their care. This study explores the factors influencing the use of CM for a child's EoE when the carer also uses CM., Materials and Methods: Carers of children aged 0-18 years with EoE participated in a national cross-sectional online survey, conducted in Australia between September 2018 and February 2019. Data analysis included bivariate analysis, Cramer's V, backwards stepwise logistic regression and binomial logistic regression., Results: Of the 181 total survey responses, 165 (91.2 %) respondents indicated they had utilized some form of CM for themselves. Children whose carer had used some form of CM for themselves were more likely to have used CM than children whose carer had not used CM (OR 4.6; p = 0.001). Of the CM self-using carers, 125 (75.8 %) had also chosen to utilize CM for their child's EoE. Use of CM in children was more likely amongst children who had used a pharmaceutical for their EoE (OR 7.51; p = 0.010), and those whose carer had consulted with "other health practitioners or health workers" for their child's EoE (OR 5.34; p < 0.001) or had consulted with a chiropractor for themselves (OR 2.70; p = 0.029)., Conclusion: High CM self-use amongst carers is associated with their decision to also use CM for their child's EoE, a concern given the absence of evidence for CM's safety and efficacy in this population. CM use in this population warrants further attention. Effective conventional medicines for EoE are limited and utilization of CM amongst children with EoE in Australia is high. The recommendation of CM for children with EoE warrants further attention given the substantial concomitant pharmaceutical care, and the absence of evidence for CM's safety and efficacy in this population. Further research into the role of CM practitioners, products, and therapies in an integrative model between CM and conventional healthcare must be undertaken., (Copyright © 2021. Published by Elsevier Ltd.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results